SMITHKLINE BEECHAM PAXIL FIRST HALF U.S. SALES ARE $158 MIL.; NEW PRODUCT SALES DRIVE STRONG DOMESTIC REVENUE GROWTH FOR J&J, PFIZER AND SCHERING-PLOUGH
Executive Summary
SmithKline Beecham's $158 mil. in U.S. sales of the antidepressant Paxil helped boost the company's U.S. pharmaceutical sales 13% for the six-month period ended June 30.